<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent treatment advances now allow a realistic chance of cure in selected patients with metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Accurate pre-treatment staging is crucial to ensure appropriate management by identification of patients with more advanced disease who will not benefit from surgery </plain></SENT>
<SENT sid="2" pm="."><plain>(18)<z:chebi fb="7" ids="24061,30236">Fluorine</z:chebi> 2-fluoro-2-deoxy-<z:chebi fb="0" ids="4167">D-glucose</z:chebi> <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography-computed tomography (PET-CT) has a firmly established role in staging, restaging, and recurrence detection of a range of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This article will review the role of PET-CT in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with a particular emphasis on optimizing the technique in patients with potentially operable <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
</text></document>